Last reviewed · How we verify
NCT04396158
Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer
NA trial testing radioactive iodine in Ovarian Insufficiency in 38 participants. Status unknown.
15 June 2021
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 38 |
| Start date | 15 June 2020 |
| Primary completion | 15 June 2021 |
| Estimated completion | 15 December 2021 |
Drugs / interventions tested
- radioactive iodine — full drug profile →
Conditions studied
- Ovarian Insufficiency — all drugs for Ovarian Insufficiency →
- Radiation Exposure — all drugs for Radiation Exposure →
Sponsor
Assiut University
Who can join
Adults 15 to 45, female only, with Ovarian Insufficiency or Radiation Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04396158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radioactive iodine
Trials testing the same drug.
- NCT05512715 — LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism · Phase 4 · completed
Other recruiting trials for Ovarian Insufficiency
Currently open trials in the same condition.
- NCT05181748 — Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders · Phase 2, PHASE3 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04396158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 27 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04396158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing